PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it will be presenting clinical data on its lead compounds, tavaborole and AN2728, at the following upcoming medical meetings:
72nd Society for Investigative Dermatology Annual Meeting – Thursday, May 10, 2012
- “Safety and Efficacy of AN2728 and AN2898 Ointments in a Phase 2a Bilateral Study of Mild-to-Moderate Atopic Dermatitis”
